The healthcare company offering VR therapies to enhance the quality of life for cancer patients, Rocket VR Health, has inked a research agreement with the Massachusetts General Hospital.
The company will use its virtual reality therapy platform to develop a VR digital therapeutic solution for the population-specific well-researched care interventions created by Massachusetts General Hospital. The Digital Therapeutic Solution will assist with distress management for blood cancer patients undergoing hematopoietic stem cell transplantation (HCT).
Sid Desai, co-founder and CEO at Rocket VR Health, said, “This research partnership is instrumental to our company’s development, and we are thrilled to be collaborating on innovative research with leading oncologists at one of the top research hospitals in the world.”
The research will examine the effects of virtual reality therapy on patients over the course of their hospital stay. On average, an individual undergoing HCT approximately stays at the hospital for 28 days. The patient cannot leave the room or interact with the outside world as their immune system is weakened. The treatment forces the patients through significant short and long-term distress that negatively impacts their quality of life, including physical and psychological well-being.
The virtual reality experience being developed will incorporate seven modules, combining psychoeducation, therapy, and relaxation exercises to be taken over a 4-week period. The immersive environments, imagery, sounds, and music on the Rocket VR Health platform will provide the patients with a gateway to the outside world that they can experience virtually while being confined in the room.
Follow us on LinkedIn
Read other Articles
